malignant hyperthermia [final]
TRANSCRIPT
![Page 1: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/1.jpg)
Malignant Hyperthermia
Presenter: Sumit GuptaModerator: Dr. Anjolie Chhabra Additional Prof. Anesthesiology
AIIMS, New Delhi
![Page 2: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/2.jpg)
Introduction
Malignant Hyperthermia Pharmaco-genetic disorder
In Genetically Susceptible. On exposure
Volatile inhalational agents & Sch. Abnormal ↑↑ intracellular Ca²⁺
Rapid ↑ Body Temperature: Hyperthermia Skeletal muscle activity
Rhabdomyolysis and metabolic acidosis → Death
Malignant
![Page 3: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/3.jpg)
HISTORY• Ist case reported ~ 1960: Australia
• Danbourough And Lovell
– 21 year/M → malleolar # fixation
– George Locher (Wisconsin) and Beverly Britt (Toronto)
• Familial disorder
• Central loss of temperature control
– Disorder of skeletal muscle metabolism
• 1966: Wilson et al
• Ist coined the term “malignant hyperthermia”
• 2001: Punj et al (IRCH): Ist case of MH in India
History of 10 anesthesia related deaths in the family
![Page 4: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/4.jpg)
PATHOPHYSIOLOGY• NORMAL PHYSIOLOGY
• STORE OPERATED CALCIUM ENTRY
1.Motor neuron
releases Ach
2.Ach binds to Ach receptors -opens Na⁺ channels & generates APs
3. AP reaches T
tubule
4. Voltage Sensor DHPR
receptors activated
5.Ca²⁺ is released from SER via Ryanodine receptor. (3isoforms: Cardiac, Skeletal, Brain). Biphasic response to Ca ²⁺ & Inhibited by Mg ²⁺
6. Ca²⁺ binds to Troponin
and promotes
actin-myosin
interaction
7. SERCA pumps propel Ca²⁺ back to the SR & cause relaxation when Ca²⁺ is <10 -7 M and require ATP
![Page 5: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/5.jpg)
PATHOPHYSIOLOGYAbn Excitation contraction Coupling
1.Motor neuron releases Ach
2.Ach binds to Ach receptors & opens Na⁺ channels & generates APs
3. AP is propagated to the T tubule
4. Voltage Sensor DHPR
receptors activated 5.Ca ² ⁺ is released
from SER via Ryanodine rececptors
6. Ca ² ⁺ then binds to Troponin facilitates
actin-myosin complex
7. SERCA propel Ca²⁺ back to SR & causes relaxation when Ca²⁺ is <10 -7
M and require ATP
![Page 6: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/6.jpg)
PATHOPHYSIOLOGY• Calcium releasing Unit (CRU)
– Key unit of Excitation Contraction Coupling
– Includes Ryanodine• Central component of CRU• Interacts with Ca²⁺ V1.1
and other proteins• Homer 1, calstabin, triadin,
junctin, junctophilin etc.– Predominantly affected by MH
mutations
![Page 7: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/7.jpg)
PATHOPHYSIOLOGYMH Mutations: AD with Variable Penetrance
↑ sensitivity•Inhalational anesthetics •Caffeine•4-chloro-m-cresol• K⁺
↓ inhibition •Ca²⁺ >10-5 M
•Mg²⁺
MOST COMMON•RyR1 (50-70%): Chr. 19q •DHPR : CACNA1s (Chr. 1) •Calsequestrin
INHERITANCE CAN VARY
![Page 8: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/8.jpg)
EVALUATION
![Page 9: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/9.jpg)
• Indications– Individuals with “MH susceptible” contracture test
• Identify the mutation involved– Can be offered as first line test if “hyperthermic reaction
under anesthesia”– Ist degree relatives of an index case
• Risk of transmission: 50%– Family member of a person +ve mutation test– Contracture test
• Not available • Refusal by patient
GENETICS AND DNA TESTING
![Page 10: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/10.jpg)
GENETICS AND DNA TESTING
DNA testing
Involves testing for Ryr1 and CACNA1s
Universal application is not possible
A negative test has to be confirmed with Contracture tests
Misses MH due to mutation of other genesMany mutations are not expressed. Can’t rule out MH susceptibility completely
![Page 11: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/11.jpg)
CONTRACTURE TEST
• Gold standard– Sensitivity & Specificity • >90%
– Detects abnormal muscle response to Halothane and caffeine.
– Requires• Muscle Harvesting: Quadriceps(MC),Rectus abdominus.
– Specimen Length: 15-25 mm, Thickness: 2-3 mm and Weight 100-150 mg (max 2-4gm).
– Local infiltration or femoral and lat. Femoral cut. nerve block.– Weight>30 Kg and age > 4 years
It is 99 % sensitive and specific. BUT1. Inter laboratory variability.2. Averages are recorded3. Accuracy of caffeine and
halothane concentrations.
![Page 12: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/12.jpg)
CONTRACTURE TEST• Indications
– History of hyperthermic reaction under GA
– Negative Genetic analysis in a suspected case
– Recurrent Rhabdomyolysis
• Record Contracture
– Caffeine > 2mmol/l and halothane >2%(IVCT)/3% (CHCT)
• Localized contracture test
– Microdialysis based– Infusion of caffiene or halothane
into muscle
– Acid base changes in muscle
+ve test: Contracture > 0.2 G Caffeine conc.<2mmol/L halothane conc. <2%
![Page 13: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/13.jpg)
CONTRACTURE TEST
IVCT
• Used in Europe
• Both Incremental Halothane
(0.5-3%) and Incremental
caffeine 0.5 -32 m mol/l are
used (2X increments).
• MH equivocal → MHs/MHc
CHCT
• Used In USA
• Halothane is used at fixed 3
% and incremental caffeine
in 2X increments.
• MH susceptible
NO DIFFERENCE BETWEEN SENSITIVITY OR SPECIFICITY AND
SIMILAR RESULTS ARE OBTAINED WITH EITHER TEST.
IF RESULT IS POSITIVE FOR EITHER CAFFEINE OR HALOTHANE
![Page 14: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/14.jpg)
CONTRACTURE TEST
MH SusceptiblePositive response to both halothane
and caffeine
MH EquivocalPositive response to either Caffeine
or halothane
MH Normal Contracture less than 2 g at Caffeine >3mmol/L or
Halothane>2%.
MH SusceptiblePositive response to both halothane
and caffeineMHc: Positive response to Caffeine MHH:Positive response to halothane.
MH Normal Contracture less than 2 g at Caffeine >3mmol/L or
Halothane>2%.
![Page 15: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/15.jpg)
Porcine stress
syndrome
Exertional Rhabdom-
yolysis
Non anesthetic MH
Myopathy↑↑ CPK
NON ANESTHETIC MHAnimal model of
Human MHAR : InbreedingHomozygous for RyRMH like syndrome with stressors:Endogenous & exogenous stressor
Assoc. with Recurrent Exertional Heat stroke also
• All MH suspectible• King
Denbourough syndrome.
Abn facies with prox. Myopathy• Central Core
diseaseCPK may be normal.+ve IVCT• Evan’s myopathy
Awake MH•MH in the absence of classical triggers•Coexistent 2nd mutation• Higher susceptibility to exogenous trigger• Extreme Physical
activity in hot surroundings
• Infectious fever
![Page 16: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/16.jpg)
NON ANESTHETIC MH
Genetic•Combined myopathy with RyR mutation.•Variable penetrance.
Diagnosis• Dilemma
• Unknown mutations• CHCT/IVCT
• Poor Sensitivity & Specificity.
• Diagnosis with different triggers/new tests.
Avoid•Heat exposure•Physical activity in Hot environment.•Febrile illness: Early t/t: Rapid Cooling •Prophlaxis: Dantrolene•Counseling to parents.NOT AUTOSOMAL
DOMINANTHeat,Oxidative stress Non invasive : P31 MRI
At Risk of MHHypertrophyMuscle HypotoniaSpasmOpthalmoplegia .
![Page 17: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/17.jpg)
COMING BACK TO ELEPHANT IN THE ROOM
![Page 18: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/18.jpg)
MH: Clinical presentation
• INCIDNCE– WORLD : 1: 10,000 – 1:220,000.– JAPAN : 1:60,000 →1:73,000.– INDIA: Under reported 16- 17 cases
Mortality:Intially: 70%.With Dantrolene: 1.4-5%
![Page 19: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/19.jpg)
Clinical Presentations• Males> females• MC in young age, muscular• ENT/DENTAL/SQUINT• Most Rapid onset halothane + Sch
• MH can occur– Previously Uneventful anesthesia exposure
MAC requirement is highest in young age
Exposed to higher dose.
Fulminant MHImmediate onset
Rapid Course
Insidious MHDelayed Onset.
Can present even in Recovery Room
TYPES
![Page 20: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/20.jpg)
PATHOGENESISTriggerSusceptibility
Absent inhibitory
factors
Persistent Ca2+Release From the SR→
Sustained Muscle
Contracture↑Skeletal Muscle
metabolic activity
HypercarbiaTachypnea.Metabolic
acidosis(↑lactate)
↑ O2 consumptionFall in SpO2Fall in SvO2.
↑ed sympathetic
activityTachycardiaArrhythmia
SweatingGeneralized
Muscle RigidityElevated Temp.
Muscle break down
CyanosisRhabdomyolyisi
sHyperKalemia
VT/VFDIC
![Page 21: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/21.jpg)
CLINICAL FEATURES
HYPERCARBIA(92%)
SIN
US TACHYCARDIA(73%)
RAPID ↑ TEMP.(65
%)
ELEVATED TEMP. (53
%)
GEN. MUSCLE RIGIDITY(41%)
TACHYPNEA( 27.1%)
SWEATING (18
%)
CYANOSIS( 9.4
%)
VT/VF
DIC
•1. HYPERCARBIA IS ALSO EARLIEST SIGN OF MH• 2. MASSTER SPASM CAN
EVEN PRECEDE HYPERCARBIA BUT
PRESENT ONLY IN 27%.
![Page 22: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/22.jpg)
CLINICAL FEATURES
• EARLY SIGNS
1. Inappropriately elevated CO2
production (↑EtCO2, ↑RR).
2. ↑O2 Consumption3. Mixed Metabolic
and Respiratory acidosis
4. Profuse Sweating.5. Mottling of skin.
1.Inappropriate tachycardia2.Cardiac arrhythmias (Ventricular ectopics &Bigemini).3.Unstabele arterial Pressure.
1.Masster Spasm with Sch.
2. Generalized Muscle rigidity
METABOLIC CARDIOVASCULAR MUSCLE
TEMPERATURE CAHANGES ARE LATE
SIGNS
![Page 23: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/23.jpg)
CLINICAL FEATURES
1. Rapid rise in Core body temperature.
2. Severe Cardiac arrhythmias.
3. Cardiac arrest.
PHYSICAL
1. HyperKalemia.2. Grossly elevated
CPK.3. Grossly elevated
Blood Myoglobin.4. Dark Colored urine5. D.I.C.
LABORATORY
•Rapid rise in Temperature and high Temperature correlate with Mortality .•Core Temperature monitoring shows mortality benefit as time to administer Dantrolene is shortened.• No benefit of skin Temperature monitoring.
![Page 24: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/24.jpg)
• Generalized Muscle Rigidity - 15 (R/o Hypothermia & Immediate awakening from GA)
• Masseter spasm after Sch - 15Rigidity
• ↑ CK after anesthesia with Sch(>20,000). - 15
• ↑CK after anesthesia w/o Sch(>10,000). - 15
• Myoglobinuria (>60mcg/ml) - 15
• Serum myoglobin > 170mcg/ml -15
• Serum K+ >6.0 meq/L(r/o renal failure.) -15
Muscle Breakdown
• EtCO2> 55 or Art. CO2> 60 with Controlled ventilation -15
• EtCO2> 60 or Art. CO2> 65 with Spont. Ventilation -15
• Inappropriate HyperCarbia. -15• Inappropriate tachypnea - 10
Respiratory Acidosis
Clinical Score
• Larach Score (1994)
![Page 25: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/25.jpg)
Clinical Score• Larach Score (1994)
• Inappropriate rapid rise in temperature- 15
• Inappropriately raised temperature >38.8◦ C in periop period- 10
Rise in Temperature
• Inappropriate sinus tachycardia -3• VT or VF- 3
Cardiac Involvement
• +ve Family H/O in 1st degree relative. - 15
• +ve Family H/O in other relatives.- 5
Family History
• BE>-8meq/L -10• pH<7.25.- 10• +ve Family H/O with +ve anesthetic
History of MH.( exclude ↑ CPK).-5• +ve Family H/O with ↑ CPK -10
Other Indicators
Grading (only the Highest Score of a Process)
SCORE1. 0
2. 3-93. 10-194. 20-345 35-496. 50+
MH RANK123456
LikelihoodAlmost never
UnlikelySome what Less
than likelySomewhat more
likelyVery likely
Certain
![Page 26: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/26.jpg)
Differential diagnosis for a “GREAT MIMIC”
• Anaphylactic reaction• Diabetic coma• Drug toxicity or abuse• Equipment malfunction with increased carbon dioxide (CO2)• Exercise hyperthermia• Hyperthyroidism• Hypoventilation or low fresh gas flow• Increased ETCO2 from laparoscopicsurgery• Insufficient anesthesia or analgesia (or both)• Intracranial free blood• Malignant neuroleptic syndrome• Muscular (Duchenne and Becker) dystrophies/Myotonias• Pheochromocytoma• Rhabdomyolysis• Sepsis
![Page 27: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/27.jpg)
TREATMENTIMMEDIATELY
Declare emergency and call for Help.Inform surgeons
Termination of SurgeryStop all Inhalational agents
Switch to Non Trigger anesthesiaHyperventilation with flow 10 L
100% O2Disconnect circuit.Inform1800-MHHYPER Monitoring
•ECG, NIBP, EtCO2•Wide bore IV•Consider CVP, Arterial early• InvestigationK+, CPK, ABG, Myoglobin, Blood sugar
![Page 28: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/28.jpg)
TREATMENT
• Dantrolene• Hydantoin derivative– 2.5 mg/kg – Max 10 mg/Kg– 20 mg/ ampoule
• 16-20 ampoules– Mixed with sterile water.
• NaOH(pH-9-10), Mannitol (isotonic)• Others solun. → precipitation.
– t1/2: 10 -15 hours– S/E: Respiratory muscle weakness, Cholestasis
![Page 29: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/29.jpg)
TREATMENT
Hyperthermia2-3 L of ice
cold saline(4 Celsius)Surface cooling,
cold sheets, ice packs in axilla and
groinTemperatur
e<38 Celsius.
AcidosisHyperventilate→normocapnia
Soda Bicarb.
HyperKalemia
50 ml 50 % D WITH 50
UNITS INSULIN.
10 ML 10% CALCIUM
GLUCONATE
DIALYSIS
ARRYTHMIASAmiodarone
3mg/kg B blocker if Persistent
Urine outputHyper
hydrationFurosemid
e 1-2mg/kgMannitol 1g/kg.
Observe for at least 24 hours in ICU.
Recrudescence risk is 50%
![Page 30: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/30.jpg)
AAGBI TEMPLATE MH
![Page 31: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/31.jpg)
AAGBI SAMPLE MH KITCOMPARTMENT 1
Dantrolene•100 ml sterile water X 12• Dantrolene X12 vials.•50 ml syringe X 10•Location of Dantrolene
COMPARTMENT 2Treatment
•Amiodarone 300 mg•ẞ Blockers•Calcium chloride/luconate•Soda bicarb 50ml•Propofol vials•Glucose 20%
COMPARTMENT 3Investigations
•Blood vials: Biochem., FBC, Coagulation, Urine Sample, Grouping•Art & CVP Canula & Transducer
COMPARTMENT 4Fridge pack
• 2l NaCl 4 degree C• Insulin
COMPARTMENT 3Investigations
•Blood vials: Biochem., FBC, Coagulation, Urine Sample, Grouping•Art & CVP Canula & Transducer
![Page 32: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/32.jpg)
Masseter Spasm• Usually seen after Sch• Jaw muscle Rigidity with whole body flaccidity > 2min.
– MH susceptibility: 30%.– Higher risk→ Jaw + whole Body rigidity
• “Jaws of steel”– Most severe variant– Ventilation and Intubation might not be possible.– Stop surgery
• Surgery– Controversial in others– To proceed or to stop
Slow Tonic fibers in Jaw muscle
GradingGrade 1: Jaw stiffness onlyGrade 2: Jaw stiffness interfering with intubationGrade 3: Jaws of Steel
![Page 33: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/33.jpg)
Drugs causing MH
• Sch• Volatile agents– HAL>ISO>ENF>SEVO.
• ONDANSETRON
![Page 34: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/34.jpg)
ANESTHESIA MH SUSCEPTIBLITY
• Avoid trigger agents• Flush the circuit with 10 L O2.• Use Charcoal filter in anesthesia machine• TIVA• Regional anesthesia.• Xenon (Case Report)
![Page 35: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/35.jpg)
Thank you
![Page 36: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/36.jpg)
PATHOPHYSIOLOGY
• SERCA pumps– Propel Ca ² ⁺ back to the SR– Relaxation
• Ca ² ⁺ is <10 -7 M– Requires ATP
• Ryanodine– SR Ca ² ⁺ release channel– 3 isoforms• Cardiac, Skeletal, Brain
– Biphasic response to Ca ²⁺– Mg ²⁺
![Page 37: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/37.jpg)
GENETICS AND DNA TESTING
• Malignant Hyperthermia– Pharamacogenetic syndrome.– Ryanodine mutations 50-80%• Chr. 19q• Associated with Myopathies
– Central core disease, Evans Myopathy.• Vary
![Page 38: Malignant hyperthermia [final]](https://reader035.vdocuments.site/reader035/viewer/2022062306/58ceb1b71a28abb2218b5123/html5/thumbnails/38.jpg)
CLINICAL PRESENTATION